Structure-based HIV-1 integrase inhibitor design: a future perspective

Bibliography

• ENGELMAN A, MIZUUCHI K, CRAIGIE R: 1-11V-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell (1991) 67:1211–1221.
   PubMed Web of Science ®Google Scholar
• BROWN PO: Integration. In: Retroviruses. Coffin JC, Hughes SH, Varmus HE (Eds.), Cold Spring Harbor Press, Cold Spring Harbor (1998).
   Google Scholar
• BUSHMAN FD: Host proteins in retroviral cDNA integration. Adv. Virus Res. (1999) 52:301–317.
   PubMed Web of Science ®Google Scholar
• FOUCHIER RAM, MALIM MH: Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv. Virus Res. (1999). 52:275–299.
   PubMed Web of Science ®Google Scholar
• KARAGEORGOS LP, BURRELL LC: Characterization ofHIV replication complexes early after cell-to-cell infection. AIDS Res. Hum. Retroviruses (1993) 9 (9):817–823.
   PubMed Web of Science ®Google Scholar
• BUKRINSKY MI, SHAROVA N, MCDONALD TL,PUSHKARSKAYA T, TARPLEY WG, STEVENSON M: Association of integrase, matrix and reverse transcrip-tase antigens of human immunodeficiency virus Type 1 with viral nucleic acids following acute infection. Proc. Nati Acad. Sci. USA (1993) 90(13):6125–6129.
   PubMed Web of Science ®Google Scholar
• FARNET CM, HASELTINE WA: Determination of viralproteins present in the human immunodeficiency virus Type 1 preintegration complex. J. Vim/ (1991) 65 (4):1910–1915.
   Web of Science ®Google Scholar
• FARNET CM, WANG B, LIPFORD JR, BUSHMAN FD: Differ-ential inhibition of HEV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Nati Acad. Sci. USA (1996) 93(18):9742–9747.
   PubMed Web of Science ®Google Scholar
• NEAMATI N, SUNDER S, POMMIER Y: Design and discovery of HIV-1 integrase inhibitors. DrugDis. Today (1997) 2:487–498.
   Web of Science ®Google Scholar
• ••Classifies and presents detailed structures of integraseinhibitors to date.
   Google Scholar
• NEAMATI N, MARCH C, POMMIER Y: IliV-1 integrase inhibitors: past, present and future. Adv. Pharmacol. (2000) 49:147–165.
   PubMedGoogle Scholar
• ••A recent review describing the latest progress in the field.
   Google Scholar
• POMMIER Y, NEAMATI N: Inhibitors of human immunodeficiency virus integrase. Adv. Virus. Res. (1999) 52:427–458.
   PubMed Web of Science ®Google Scholar
• ••A review with detailed analysis of integrase function andinhibitor design.
   Google Scholar
• POMMIER Y, MARCH C, NEAMATI N: Retr ovir al integraseinhibitors year 2000: update and perspectives. Antiviral Res. (2000) 47(3):139–148.
   PubMed Web of Science ®Google Scholar
• HAZUDA DJ, FELOCK P, WITMER M et al.: Inhibitors of strand transfer that prevent integration and inhibit HIV- 1 replication in cells. Science (2000) 287 (5453):646–650.
   PubMed Web of Science ®Google Scholar
• ••Describes the first bona fide inhibitor of integrase andvalidates integrase as the target for diketo acids.
   Google Scholar
• ESPESETH AS, FELOCK P, WOLFE A et al.: HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA (2000) 97:11244–11249.
   PubMed Web of Science ®Google Scholar
• SKINNER LM, SUDOL M, HARPER AL, KATZMAN M: Nucleophile selection for the endonuclease activities of human, ovine and avian retroviral integrases. J. Biol. Chem. (2000) 276:114–124.
   Web of Science ®Google Scholar
• KOSTREWA D, WINKLER FK: Mg 2± binding to the activesite of EcoRV endonuclease: a crystallographic study of complexes with substrate and product DNA at 2 A resolution. Biochemistry (1995) 34 (2) : 683–696.
   PubMed Web of Science ®Google Scholar
• BUJACZ G, ALEXANDRATOS J, WLODAWER A, MERKEL G,ANDRAKE M, KATZ RA, SKALKA AM: Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. (1997) 272(29):18161–18168.
   PubMed Web of Science ®Google Scholar
• KASHO VN, STENGELIN M, SMIRNOVA IN, FALLER LD: Aproposal for the Mg2+ binding site of P-type ion motive AlPases and the mechanism of phosphoryl group transfer. Biochemistry (1997) 36 (26):8045–8052.
   PubMed Web of Science ®Google Scholar
• BEESE LS, STEITZ TA: Structural basis for the 3'-S'exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO (1991) 10(1):25–33.
   PubMed Web of Science ®Google Scholar
• NUNN CM, NEIDLE S: The high resolution crystalstructure of the DNA decamer d(AGGCATGCC1). Mol. Biol. (1996) 256(2):340–351.
   Web of Science ®Google Scholar
• WLODAWER A: Crystal structures of catalytic coredomains of retroviral integrases and role of divalent cations in enzymatic activity. Adv. Virus. Res. (1999) 52:335–350.
   PubMed Web of Science ®Google Scholar
• ASANTE-APPIAH E, SKALKA AM: HIV-1 integrase: structural organization, conformational changes and catalysis. Adv. Virus. Res. (1999) 52:351–369.
   PubMed Web of Science ®Google Scholar
• STANVVELL C, YE B, YUSPA SH, BURKE TR JR: Cell protein cross-linking by erbstatin and related compounds. Biochem. Pharmacol. (1996) 52(3):475–480.
   PubMed Web of Science ®Google Scholar
• •Describes a mechanism of binding of catechol-containing compounds to proteins.
   Google Scholar
• FARNET CM, BUSHMAN FD: HLV cDNA integration: molecular biology and inhibitor development. AIDS (1996) 1 0 (Suppl. A):S3–11.
   Google Scholar
• THOMAS M, BRADY L: HLV integrase: a target for AIDS therapeutics. Trends Biotechnol. (1997) 15(5)167–172.
   Google Scholar
• ASANTE-APPIAH E, SKALKA AM: Molecular mechanisms in retrovirus DNA integration. Antiviral Res. (1997) 36 (3):139–156.
   PubMed Web of Science ®Google Scholar
• POMMIER Y et al.: HIV-1 integrase as a target for antiviral drugs. Antiviral Chem. Chemother. (1997) 8:463–483.
   Web of Science ®Google Scholar
• HANSEN MS, CARTEAU S, HOFFMANN C, LI L, BUSHMAN F: Retroviral cDNA integration: mechanism, applica-tions and inhibition. Genet. Eng. (1998) 20:41–61.
   Google Scholar
• ROBINSON JW: _my integrase: the next target? Infect. Med. (1998) 15:129–137.
   Web of Science ®Google Scholar
• PANI A, MARONGIU ME: AntiHIV-1 integrase drugs: how far from the shelf? Curr. Pharm. Des. 2000. 6 (5):569–584.
   Google Scholar
• DYDA F, HICKMAN AB, JENKINS TM, ENGELMAN A, CRAIGIE R, DAVIES DR: Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynu- cleo tidy 1tr an s fer as es.Science(1994)266(5193):1981–1986.
   PubMed Web of Science ®Google Scholar
• •First crystal structure of HIV-1 integrase core domain.
   Google Scholar
• BUJACZ G, ALEXANDRATOS J, QING ZL, CLEMENT-MELLA C, WLODAWER A: The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185Hmutant. FEBS Lett. (1996) 398 (2-3) :175–178.
   PubMed Web of Science ®Google Scholar
• •Crystal structure of HIV-1 integrase.
   Google Scholar
• MAIGNAN S, GUILLOTEAU JP, ZHOU-LIU Q, CLEMENT- MELLA C, MIKOL V: Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal co-factor: high level of similarity of the active site with other viral integrases. J Mol. Biol. (1998) 282 (2):359–368.
   PubMed Web of Science ®Google Scholar
• •Crystal structure of HIV-1 integrase.
   Google Scholar
• GOLDGUR Y, DYDA F, HICKMAN AB, JENKINS TM, CRAIGIE R, DAVIES DR: Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. USA (1 9 9 8) 95 (16) :9150-9154.
   Google Scholar
• •Improved structure of the reference 31.
   Google Scholar
• CHEN JC, KRUCINSKI J, MIERCKE LJ et al.: Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA (2000) 97(15):8233–8238. First structure of HIV-1 integrase core and C-terminal domain.
   Google Scholar
• BUJACZ G, JASKOLSKI M, ALEXANDRATOS J et al. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. j Mol. Biol. (1995) 253 (2):333–346.
   PubMed Web of Science ®Google Scholar
• LUBKOWSKI J, DAUTER Z, YANG F et al.: Atomic resolu- tion structures of the core domain of avian sarcoma virus integrase and its D64N mutant. Biochemistry (1999) 38(45):15060.
   PubMed Web of Science ®Google Scholar
• •Describes a high-resolution structure of ASV integrase.
   Google Scholar
• CHEN Z, YAN Y, MUNSHI S et al.: X-ray structure of simian immunodeficiency virus integrase containing the core and c-terminal domain (residues 50-293) - an initial glance of the viral dna binding platform. J Mol. Biol. (2000) 296(2): 521–533.
   PubMed Web of Science ®Google Scholar
• •First structure of the SIV-1 integrase core and C-terminal domain.
   Google Scholar
• LUBKOWSKI J, YANG F, ALEXANDRATOS J, et al.: Structure of the catalytic domain of avian sarcoma virus integrase with a bound IRV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. USA (1 9 9 8) 95 (9):4831–4836.
   Google Scholar
• ••First crystal structure of an inhibitor with ASV integrase.
   Google Scholar
• GOLDGUR Y, CRAIGIE R, COHEN GH et al.: Structure of the IRV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA (1999) 96(23):13040–13043.
   PubMed Web of Science ®Google Scholar
• ••First crystal structure of an inhibitor with HIV-1 integrase.
   Google Scholar
• GUNER OF: Pharmacophore perception, development and use in drug design. International University Line. (2000).
   Google Scholar
• NICKLAUS MC, NEAMATI N, HONG H et al.: integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. (1997) 40(6):920–929.
   PubMed Web of Science ®Google Scholar
• HONG H, NEAMATI N, WANG S et al.: Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med. Chem. (1997) 40(6):930–936.
   PubMed Web of Science ®Google Scholar
• HONG H, NEAMATI N, WINSLOW HE et al.: Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir. Chem. Chemother. (1998) 9 (6):461–472.
   PubMed Web of Science ®Google Scholar
• NEAMATI N, HONG H, MAZUMDER A et al.: Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J Med. Chem. (1997) 40(6):942–951.
   PubMed Web of Science ®Google Scholar
• NEAMATI N, HONG H, SUNDER S, MILNE GW, POMMIERY: Potent inhibitors of human immunodeficiency virus Type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. (1997) 52(6):1041–1055.
   PubMed Web of Science ®Google Scholar
• CARLSON HA, MASUKAWA KM, RUBINS K et al.: Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. (2000) 43(11):2100–2114.
   PubMed Web of Science ®Google Scholar
• DRAKE RR, NEAMATI N, HONG H et al.: Identification of the antiviral nucleoside drug binding site of HIV-1 integrase by proteolytic peptide mapping. Antiviral Res. (1997) 34:A42.
   Google Scholar
• DRAKE RR, NEAMATI N, HONG H et al.: Identification of a nucleotide binding site in HIV-1 integrase. Proc. Natl. Acad. Sci. USA (1998) 95(8):4170–4175.
   PubMed Web of Science ®Google Scholar
• ••First report of drug (mononucleotide)-binding site onintegrase.
   Google Scholar
• HEUER TS, BROWN PO: Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus Type 1 in tegr ase-DNA complex. Biochemistry (1998) 37 (19):6667–6678.
   PubMed Web of Science ®Google Scholar
• HEUER TS, BROWN PO: Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross- linking. Biochemistry (1997) 36(35):10655–10665.
   PubMed Web of Science ®Google Scholar
• JENKINS TM, ESPOSITO D, ENGELMAN A, CRAIGIE R: Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO. J. (1997) 16(22):6849–6859.
   PubMed Web of Science ®Google Scholar
• ESPOSITO D, CRAIGIE R: HLV integrase structure and function. Adv. Virus. Res. (1999) 52:319–333.
   PubMed Web of Science ®Google Scholar
• ESTE JA, CABRERA C, SCHOLS D et al.: Human immuno-deficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. (1998) 53(2):340–345.
   PubMed Web of Science ®Google Scholar
• PLUYMERS W, NEAMATI N, PANNECOUQUE C et al.: Viral entry as the primary target for the antilliV activity of chicoric acid and its tetra-acetyl esters. Ma Pharmacol. (2000) 58(3):641–648.
   PubMed Web of Science ®Google Scholar
• •Argues against the previous reports on the validity of chicoric acids as integrase inhibitors.
   Google Scholar
• CHEN IJ, NEAMATI N, NICKLAUS MC et al.: Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorg. Med. Chem. (2000) 8(10):2385–2398.
   PubMed Web of Science ®Google Scholar
• ••First report of database searching by docking a large numberof compounds on the integrase crystal structure.
   Google Scholar
• SOTRIFFER CA, NI H, MCCAMMON JA: Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. (2000) 43(22):4109–4117.
   PubMed Web of Science ®Google Scholar
• ••Describes docking of several reported inhibitors on theintegrase core domain.
   Google Scholar
• CAI M, ZHENG R, CAFFREY M, CRAIGIE R, CLORE GM, GRONENBORN AM: Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nature Struct. Biol. (1997) 4(7): 567–577.
   PubMedGoogle Scholar
• CAI M, HUANG Y, CAFFREY M et al.: Solution structure of the Ilis12 Cys mutant of the N-terminal zinc binding domain of HIV-1 integrase complexed to cadmium. Protein Sci. (1998) 7(12):2669–2674.
   PubMed Web of Science ®Google Scholar
• •Describes the structure of HIV-1 N-terminal domain by NMR.
   Google Scholar
• EIJKELENBOOM AP, VAN DEN ENT FM, VOS A, DORELEIJERS JF et al.: The solution structure of the amino-terminal HUICC domain of PIIV-2 integrase: a three-helix bundle stabilized by zinc. Curr. Biol. (1997) 7 (10):739–746.
   Google Scholar
• EIJKELENBOOM AP, VAN DEN ENT FM, WECHSELBERGER R, PLASTERK RH, KAPTEIN R, BOELENS R: Refined solution structure of the dimeric N-terminal 1-111CC domain of HIV-2 integrase. J. Biomol. (2000) 18(2):119–128.
   Web of Science ®Google Scholar
• •Describes a new structure of HIV-2 N-terminal domain by NMR.
   Google Scholar
• MACKAY JP, CROSSLEY M: Zinc fingers are sticking together. Trends Biochem. Sci. (1998) 23(1):1–4.
   PubMed Web of Science ®Google Scholar
• MASUDA T, PLANELLES V, KROGSTAD P, CHEN IS: Genetic analysis of human immunodeficiency virus Type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain./ Viral. (1995) 69(11):6687–6696.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, MASUDA T, GOTO T, SANO K, NAKAI M, HARADA S: Lack of infectivity of 1-11V-1 integrase zinc finger-like domain mutant with morphologically normal maturation. Biochem. Biophys. Res. CO177177017. (1997) 239(3):715–722.
   Google Scholar
• BERG JM, GODWIN HA: Lessons from zinc-binding peptides. Ann. Rev. Biophys. Biomol. Struct. (1997) 26:357–371.
   PubMedGoogle Scholar
• CHOO Y, KLUG A: Physical basis of a protein-DNA recognition code. Curr. Opin. Struct. Biol. (1997) 7(1):117–125.
   PubMed Web of Science ®Google Scholar
• RICE WG, TURPIN JA: Virus-encoded zinc fingers as targets for antiviral chemotherapy. Rev. Med. Viral. (1996) 6:187–199.
   PubMed Web of Science ®Google Scholar
• WU H, YANG WP, BARBAS CF 3RD: Building zinc fingersby selection: toward a therapeutic application. Proc. Natl. Acad. Sci. USA (1995) 92(2):344–348.
   PubMed Web of Science ®Google Scholar
• YI J, ARTHUR JW, DUNBRACK RL JR, SKALKA AM: An inhibitory monoclonal antibody binds at the turn of the 11TH motif in the N-terminal domain of 111V-1 integrase. J. Biol. Chem. (2000)
   Google Scholar
• EIJKELENBOOM AP, LUTZKE RA, BOELENS R, PLASTERK RH, KAPTEIN R, HARD K: The DNA-binding domain of ERV-1 integrase has an SH3-like fold. Nature Struct. Biol. (1995) 2(9):807–810.
   PubMedGoogle Scholar
• EIJKELENBOOM AP, SPRANGERS R, HARD K ET AL: et al.,Refined solution structure of the C-terminal DNA-binding domain of human immun ovir us-1 integrase. Proteins (1999) 36(4):556–564.
   Google Scholar
• LODI PJ, ERNST JA, KUSZEWSKI J, HICKMAN AB: Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry (1995) 34(31):9826–9833.
   PubMed Web of Science ®Google Scholar
• SMITHGALL TE: 5I-12 and 5I-13 domains: potential targets for anticancer drug design. J. Pharmacol. Toxicol. Methods (1995) 34(3):125–132.
   PubMed Web of Science ®Google Scholar
• FLETCHER TM 3RD, SOARES MA, MCPHEARSON S: Complementation of in tegr ase function in ERV-1 virions. EMBO. J (1997) 16 (16):5123–5138.
   PubMed Web of Science ®Google Scholar
• DIVITA G, RESTLE T, GOODY RS, CHERMANN JC, BAILLON JG: Inhibition of human immunodeficiency virus Type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. (1994) 269:13080–13083.
   PubMed Web of Science ®Google Scholar
• SCHRAMM HJ, BOETZEL J, BUTTNER J et al.: The inhibi-tion of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res. (1996) 30 (2-3):155–170.
   PubMed Web of Science ®Google Scholar
• QUERE L, WENGER T, SCHRAMM HJ: Triterpenes as potential dimerization inhibitors of FIEV-1 protease. Biochem. Biophys. Res. Commun. (1996) 227 (2):484–488.
   PubMed Web of Science ®Google Scholar
• MCPHEE F, GOOD AC, KUNTZ ID, CRAIK CS: Engineering human immunodeficiency virus 1 protease hetero-dimers as macromolecular inhibitors of viral matura-tion. Proc. Natl. Acad. Sci. USA (1996) 93(21):11477–11481.
   PubMed Web of Science ®Google Scholar
• MCMILLAN K, ADLER M, AULD DS etal.: Allosteric inhibi-tors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Nail. Acad. Sci. USA (2000) 97(4):1506–1511.
   Google Scholar
• GALLAY P, HOPE T, CHIN D, TRONO D: HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA (1997) 94(18):9825–9830.
   PubMed Web of Science ®Google Scholar
• POPOV S, REXACH M, RATNER L, BLOBEL G, BUKRINSKY M: Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO. J. (1998) 17(4):909–917.
   PubMed Web of Science ®Google Scholar
• GULIZIA J, DEMPSEY MP, SHAROVA N et al.: Reduced nuclear import of human immunodeficiency virus Type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J Vim/. (1994) 68 (3):2021–2025. three-helix bundle stabilized by zinc. Curr. Biol. (1997) 7 (10):739–746.
   Google Scholar
• EIJKELENBOOM AP, VAN DEN ENT FM, WECHSELBERGER R, PLASTERK RH, KAPTEIN R, BOELENS R: Refined solution structure of the dimeric N-terminal 1-111CC domain of HIV-2 integrase. J. Biomol. (2000) 18(2):119–128.
   Web of Science ®Google Scholar
• •Describes a new structure of HIV-2 N-terminal domain by NMR.
   Google Scholar
• MACKAY JP, CROSSLEY M: Zinc fingers are sticking together. Trends Biochem. Sci. (1998) 23(1):1–4.
   PubMed Web of Science ®Google Scholar
• MASUDA T, PLANELLES V, KROGSTAD P, CHEN IS: Genetic analysis of human immunodeficiency virus Type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain./ Viral. (1995) 69(11):6687–6696.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, MASUDA T, GOTO T, SANO K, NAKAI M, HARADA S: Lack of infectivity of 1-11V-1 integrase zinc finger-like domain mutant with morphologically normal maturation. Biochem. Biophys. Res. CO177177017. (1997) 239(3):715–722.
   Google Scholar
• BERG JM, GODWIN HA: Lessons from zinc-binding peptides. Ann. Rev. Biophys. Biomol. Struct. (1997) 26:357–371.
   PubMedGoogle Scholar
• CHOO Y, KLUG A: Physical basis of a protein-DNA recognition code. Curr. Opin. Struct. Biol. (1997) 7(1):117–125.
   PubMed Web of Science ®Google Scholar
• RICE WG, TURPIN JA: Virus-encoded zinc fingers as targets for antiviral chemotherapy. Rev. Med. Viral. (1996) 6:187–199.
   PubMed Web of Science ®Google Scholar
• WU H, YANG WP, BARBAS CF 3RD: Building zinc fingersby selection: toward a therapeutic application. Proc. Natl. Acad. Sci. USA (1995) 92(2):344–348.
   PubMed Web of Science ®Google Scholar
• YI J, ARTHUR JW, DUNBRACK RL JR, SKALKA AM: An inhibitory monoclonal antibody binds at the turn of the 11TH motif in the N-terminal domain of 111V-1 integrase. J. Biol. Chem. (2000)
   Google Scholar
• EIJKELENBOOM AP, LUTZKE RA, BOELENS R, PLASTERK RH, KAPTEIN R, HARD K: The DNA-binding domain of ERV-1 integrase has an SH3-like fold. Nature Struct. Biol. (1995) 2(9):807–810.
   PubMedGoogle Scholar
• EIJKELENBOOM AP, SPRANGERS R, HARD K ET AL: et al.,Refined solution structure of the C-terminal DNA-binding domain of human immun ovir us-1 integrase. Proteins (1999) 36(4):556–564.
   Google Scholar
• LODI PJ, ERNST JA, KUSZEWSKI J, HICKMAN AB: Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry (1995) 34(31):9826–9833.
   PubMed Web of Science ®Google Scholar
• SMITHGALL TE: 5I-12 and 5I-13 domains: potential targets for anticancer drug design. J. Pharmacol. Toxicol. Methods (1995) 34(3):125–132.
   PubMed Web of Science ®Google Scholar
• FLETCHER TM 3RD, SOARES MA, MCPHEARSON S: Complementation of in tegr ase function in ERV-1 virions. EMBO. J (1997) 16 (16):5123–5138.
   PubMed Web of Science ®Google Scholar
• DIVITA G, RESTLE T, GOODY RS, CHERMANN JC, BAILLON JG: Inhibition of human immunodeficiency virus Type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. (1994) 269:13080–13083.
   PubMed Web of Science ®Google Scholar
• SCHRAMM HJ, BOETZEL J, BUTTNER J et al.: The inhibi-tion of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res. (1996) 30 (2-3):155–170.
   PubMed Web of Science ®Google Scholar
• QUERE L, WENGER T, SCHRAMM HJ: Triterpenes as potential dimerization inhibitors of FIEV-1 protease. Biochem. Biophys. Res. Commun. (1996) 227 (2):484–488.
   PubMed Web of Science ®Google Scholar
• MCPHEE F, GOOD AC, KUNTZ ID, CRAIK CS: Engineering human immunodeficiency virus 1 protease hetero-dimers as macromolecular inhibitors of viral matura-tion. Proc. Natl. Acad. Sci. USA (1996) 93(21):11477–11481.
   PubMed Web of Science ®Google Scholar
• MCMILLAN K, ADLER M, AULD DS etal.: Allosteric inhibi-tors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Nail. Acad. Sci. USA (2000) 97(4):1506–1511.
   Google Scholar
• GALLAY P, HOPE T, CHIN D, TRONO D: HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA (1997) 94(18):9825–9830.
   PubMed Web of Science ®Google Scholar
• POPOV S, REXACH M, RATNER L, BLOBEL G, BUKRINSKY M: Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO. J. (1998) 17(4):909–917.
   PubMed Web of Science ®Google Scholar
• GULIZIA J, DEMPSEY MP, SHAROVA N et al.: Reduced nuclear import of human immunodeficiency virus Type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J Vim/. (1994) 68 (3):2021–2025.
   Web of Science ®Google Scholar